{ "labelLang" : "hun", "responseDate" : "2024-03-29 14:25", "content" : { "otype" : "JournalArticle", "mtid" : 22707462, "status" : "VALIDATED", "published" : true, "unhandledTickets" : 0, "oldTimestamp" : "2018-10-01T21:39:06.000+0000", "deleted" : false, "oldId" : 12707462, "lastRefresh" : "2023-07-06T20:51:09.738+0000", "lastModified" : "2020-12-14T10:30:46.872+0000", "created" : "2012-11-21T10:36:43.000+0000", "creator" : { "otype" : "Author", "mtid" : 10006282, "link" : "/api/author/10006282", "label" : "Rajna Péter (Ideg és elmegyógyászat)", "familyName" : "Rajna", "givenName" : "Péter", "published" : true, "oldId" : 10006282, "snippet" : true }, "validated" : "2020-12-14T10:30:26.260+0000", "validator" : { "otype" : "Admin", "mtid" : 565, "link" : "/api/admin/565", "label" : "WoS import (admin)", "familyName" : "WoS", "givenName" : "import", "published" : true, "snippet" : true }, "core" : false, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 1134514, "link" : "/api/subtype/1134514", "label" : "Összefoglaló cikk (Folyóiratcikk)", "name" : "Összefoglaló cikk", "nameEng" : "Survey paper", "docType" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "listPosition" : 102, "published" : true, "oldId" : 1134514, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "firstAuthor" : "Figgitt, DP", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 20797465, "link" : "/api/authorship/20797465", "label" : "Figgitt, DP", "listPosition" : 1, "share" : 0.0, "first" : true, "last" : false, "familyName" : "Figgitt", "givenName" : "DP", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 29689209, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 20797466, "link" : "/api/authorship/20797466", "label" : "McClellan, KJ", "listPosition" : 2, "share" : 0.0, "first" : false, "last" : true, "familyName" : "McClellan", "givenName" : "KJ", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 29689208, "snippet" : true } ], "title" : "Fluvoxamine: An updated review of its use in the management of adults with anxiety disorders", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 18224740, "link" : "/api/publicationidentifier/18224740", "label" : "DOI: 10.2165/00003495-200060040-00006", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "10.2165/00003495-200060040-00006", "realUrl" : "https://doi.org/10.2165/00003495-200060040-00006", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 18224739, "link" : "/api/publicationidentifier/18224739", "label" : "WoS: 000165137500007", "source" : { "otype" : "PlainSource", "mtid" : 1, "link" : "/api/publicationsource/1", "label" : "WoS", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "WoS", "nameEng" : "WoS", "linkPattern" : "https://www.webofscience.com/wos/woscc/full-record/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 1, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "000165137500007", "realUrl" : "https://www.webofscience.com/wos/woscc/full-record/000165137500007", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 5480154, "link" : "/api/publicationidentifier/5480154", "label" : "Scopus: 0033762398", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "NO", "idValue" : "0033762398", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-0033762398", "published" : false, "oldId" : 2670161, "snippet" : true } ], "journal" : { "otype" : "Journal", "mtid" : 1349, "link" : "/api/journal/1349", "label" : "DRUGS 0012-6667 1179-1950", "pIssn" : "0012-6667", "eIssn" : "1179-1950", "reviewType" : "REVIEWED", "noIF" : false, "sciIndexed" : true, "scopusIndexed" : true, "lang" : "FOREIGN", "hungarian" : false, "published" : true, "oldId" : 1349, "snippet" : true }, "volume" : "60", "issue" : "4", "firstPage" : "925", "lastPage" : "954", "firstPageOrInternalIdForSort" : "925", "pageLength" : 30, "publishedYear" : 2000, "digital" : null, "printed" : null, "sourceYear" : 2012, "packet" : "(Rajna Péter (Ideg és elmegyógyászat...); 2012.11.21. 11:35:16)", "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : null, "missingAuthor" : false, "oaType" : "NONE", "oaCheckDate" : "2023-07-06", "oaFree" : false, "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "independentCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 2, "citedCount" : 2, "ratings" : [ { "otype" : "SjrRating", "mtid" : 6148520, "link" : "/api/sjrrating/6148520", "label" : "sjr:D1 (2000) Scopus - Pharmacology (medical) DRUGS 0012-6667", "listPos" : 15, "rankValue" : 0.1, "type" : "journal", "ratingType" : { "otype" : "RatingType", "mtid" : 10002, "link" : "/api/ratingtype/10002", "label" : "sjr", "code" : "sjr", "published" : true, "snippet" : true }, "subject" : { "otype" : "ClassificationExternal", "mtid" : 2736, "link" : "/api/classificationexternal/2736", "label" : "Scopus - Pharmacology (medical)", "published" : true, "oldId" : 2736, "snippet" : true }, "ranking" : "D1", "calculation" : "DIRECT", "published" : true, "oldId" : 6148520, "snippet" : true } ], "ratingsForSort" : "D1", "references" : [ { "otype" : "Reference", "mtid" : 14982257, "link" : "/api/reference/14982257", "label" : "1. Costa e Silva, J.A., The public health impact of anxiety disorders: A WHO perspective (1998) Acta Psychiatr Scand, 98 (SUPPL. 393), pp. 2-5", "listPosition" : 1, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982258, "link" : "/api/reference/14982258", "label" : "2. Kessler, R.C., McGonagle, K.A., Zhao, S., Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey (1994) Arch Gen Psychiatry, 51, pp. 8-19", "listPosition" : 2, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982259, "link" : "/api/reference/14982259", "label" : "3. Rice, D.P., Miller, L.S., Health economics and cost implications of anxiety disorders and other mental disorders in the United States (1998) Br J Psychiatry, 173 (SUPPL. 34), pp. 4-9", "listPosition" : 3, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982260, "link" : "/api/reference/14982260", "label" : "4. Sheehan, D.V., New treatments for anxiety disorders: Clinical approaches for successful outcomes (1999) J Clin Psychiatry, 60 (SUPPL. 18), p. 3", "listPosition" : 4, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982261, "link" : "/api/reference/14982261", "label" : "5. Park, L.T., Jefferson, J.W., Greist, J.H., Obsessive-compulsive disorder: Treatment options (1997) CNS Drugs, 7 (3), pp. 187-202", "listPosition" : 5, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982262, "link" : "/api/reference/14982262", "label" : "6. Treatment of posttraumatic stress disorder (1999) J Clin Psychiatry, 60 (SUPPL. 16), pp. 1-76", "listPosition" : 6, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982263, "link" : "/api/reference/14982263", "label" : "7. Treatment of obsessive-compulsive disorder (1997) J Clin Psychiatry, 58 (SUPPL. 4), pp. 1-72", "listPosition" : 7, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982264, "link" : "/api/reference/14982264", "label" : "8. Ballenger, J.C., Davidson, J.R.T., Lecrubier, Y., Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety (1998) J Clin Psychiatry, 59 (SUPPL. 8), pp. 47-54", "listPosition" : 8, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982265, "link" : "/api/reference/14982265", "label" : "9. Ballenger, J.C., Davidson, J.R.T., Lecrubier, Y., Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety (1998) J Clin Psychiatry, 59 (SUPPL. 17), pp. 54-60", "listPosition" : 9, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982266, "link" : "/api/reference/14982266", "label" : "10. Wilde, M.I., Plosker, G.L., Benfield, P., Fluvoxamine: An updated review of its pharmacology, and therapeutic use in depressive illness (1993) Drugs, 46, pp. 895-924. , Nov", "listPosition" : 10, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982267, "link" : "/api/reference/14982267", "label" : "11. Benfield, P., Ward, A., Fluvoxamine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness (1986) Drugs, 32, pp. 313-334", "listPosition" : 11, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982268, "link" : "/api/reference/14982268", "label" : "12. Palmer, K.J., Benfield, P., Fluvoxamine: An overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders (1994) CNS Drugs, 1 (1), pp. 57-87. , Jan", "listPosition" : 12, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982269, "link" : "/api/reference/14982269", "label" : "13. Claassen, V., Review of the animal pharmacology and pharmacokinetics of fluvoxamine (1983) Br J Clin Pharmacol, 15 (SUPPL. 3), pp. 349S-355S", "listPosition" : 13, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982270, "link" : "/api/reference/14982270", "label" : "14. Claassen, V., Davies, J.E., Hertting, G., Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor (1977) Br J Pharmacol, 60, pp. 505-516", "listPosition" : 14, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982271, "link" : "/api/reference/14982271", "label" : "15. Hyttel, J., Larsen, J.-J., Serotonin-selective antidepressants (1985) Acta Pharmacol Toxicol, 56 (1), pp. 146-153", "listPosition" : 15, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982272, "link" : "/api/reference/14982272", "label" : "16. Constantinidis, J., Dick, P., Tissot, R., Antidepressants and serotonin neurons of the raphe (1981) Neuropsychobiology, 7, pp. 113-121", "listPosition" : 16, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982273, "link" : "/api/reference/14982273", "label" : "17. Bel, N., Artigas, F., Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: An in vivo microdialysis study (1992) Eur J Pharmacol, 229, pp. 101-103", "listPosition" : 17, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982274, "link" : "/api/reference/14982274", "label" : "18. Ortiz, J., Artigas, F., Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: Different effects of clomipramine and fluoxetine (1992) Br J Pharmacol, 105, pp. 941-946", "listPosition" : 18, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982275, "link" : "/api/reference/14982275", "label" : "19. Benfield, P., Heel, R.C., Lewis, S.P., Fluoxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness (1986) Drugs, 32, pp. 482-508", "listPosition" : 19, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982276, "link" : "/api/reference/14982276", "label" : "20. Dechant, K.L., Clissold, S.P., Paroxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness (1991) Drugs, 41, pp. 225-253", "listPosition" : 20, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982277, "link" : "/api/reference/14982277", "label" : "21. Murdoch, D., McTavish, D., Sertraline: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder (1992) Drugs, 44, pp. 604-624", "listPosition" : 21, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982278, "link" : "/api/reference/14982278", "label" : "22. Alexander, B.S., Wood, M.D., [3H]8-OH-DPAT labels the 5-hydroxytryptamine uptake recognition site and the 5-HT(1A) binding site in the rat striatum (1988) J Pharm Pharmacol, 40, pp. 888-891", "listPosition" : 22, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982279, "link" : "/api/reference/14982279", "label" : "23. Jenck, F., Moreau, J.-L., Mutel, V., Evidence for a role of 5-HT(1C) receptors in the antiserotonergic properties of some antidepressant drugs (1993) Eur J Pharmacol, 231, pp. 223-229", "listPosition" : 23, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982280, "link" : "/api/reference/14982280", "label" : "24. Thomas, D.R., Nelson, D.R., Johnson, A.M., Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor (1987) Psychopharmacology, 93, pp. 193-200", "listPosition" : 24, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982281, "link" : "/api/reference/14982281", "label" : "25. Wong, D.T., Bymaster, F.P., Reid, L.R., Fluoxetine and two other serotonin reuptake inhibitors without affinity for neuronal receptors (1983) Biochem Pharmacol, 32, pp. 1287-1293", "listPosition" : 25, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982282, "link" : "/api/reference/14982282", "label" : "26. Hall, H., Sallemark, M., Wedel, I., Acute effects of atypical antidepressants on various receptors in the rat brain (1984) Acta Pharmacol Toxicol, 54, pp. 379-384", "listPosition" : 26, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982283, "link" : "/api/reference/14982283", "label" : "27. Heel, R.C., Morley, P.A., Brogden, N., Zimelidine: A review of its pharmacological properties and therapeutic efficacy in depressive illness (1982) Drugs, 24, pp. 169-206", "listPosition" : 27, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982284, "link" : "/api/reference/14982284", "label" : "28. Richelson, E., Nelson, A., Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro (1984) J Pharmacol Exp Ther, 230, pp. 94-102", "listPosition" : 28, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982285, "link" : "/api/reference/14982285", "label" : "29. Narita, N., Hashimoto, K., Tomitaka, S.-I., Interactions of selective serotonin reuptake inhibitors with subtypes of σ receptors in rat brain (1996) Eur J Pharmacol, 20 Jun (307), pp. 117-119", "listPosition" : 29, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982286, "link" : "/api/reference/14982286", "label" : "30. Horton, R.W., Lowther, S., Crompton, M.R., The interaction of selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) with sigma (σ) binding sites in human brain tissue (1994) Can J Physiol Pharmacol, 72 (SUPPL. 1), p. 442", "listPosition" : 30, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982287, "link" : "/api/reference/14982287", "label" : "31. Flett, S.R., Szabadi, E., Bradshaw, C.M., A comparison of the effects of fluvoxamine and amitriptyline on autonomic functions in healthy volunteers (1992) Eur J Clin Pharmacol, 42, pp. 529-533", "listPosition" : 31, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982288, "link" : "/api/reference/14982288", "label" : "32. Wilson, W.H., Higano, H., Papadatos, Y., A double-blind placebo-controlled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers (1983) Br J Clin Pharmacol, 15 (SUPPL. 3), pp. 385S-392S", "listPosition" : 32, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982289, "link" : "/api/reference/14982289", "label" : "33. Robinson, J.F., Doogan, D.P., A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers (1982) Br J Clin Pharmacol, 14, pp. 805-808", "listPosition" : 33, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982290, "link" : "/api/reference/14982290", "label" : "34. Hewer, W., Rost, W., Gattaz, W.F., Cardiovascular effects of fluvoxamine and maprotiline in depressed patients (1995) Eur Arch Psychiatry Clin Neurosci, 246, pp. 1-6. , Dec", "listPosition" : 34, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982291, "link" : "/api/reference/14982291", "label" : "35. Hochberg, H.M., Kanter, D., Houser, V.P., Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: One years experience (1995) Pharmacopsychiatry, 28, pp. 253-256. , Nov", "listPosition" : 35, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982292, "link" : "/api/reference/14982292", "label" : "36. Laird, L.K., Lydiard, B., Morton, A., Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients (1993) J Clin Psychiatry, 54 (6), pp. 224-228. , Jun", "listPosition" : 36, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982293, "link" : "/api/reference/14982293", "label" : "37. Krijzer, F., Snelder, M., Bradford, D., Comparison of the (pro) convulsive properties of fluvoxamine and clomipramine with eight other antidepressants in an animal model (1984) Neuropsychobiology, 12, pp. 249-254", "listPosition" : 37, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982294, "link" : "/api/reference/14982294", "label" : "38. Saletu, B., Grunberger, J., Rajna, P., Pharmaco-EEG profiles of antidepressants. Pharmacodynamic studies with fluvoxamine (1983) Br J Clin Pharmacol, 15 (SUPPL. 3), pp. 369S-384S", "listPosition" : 38, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982295, "link" : "/api/reference/14982295", "label" : "39. Linnoila, M., Stapleton, J.M., George, D.T., Effects of fluvoxamine, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers (1993) J Clin Psychopharmacol, 13 (3), pp. 175-180", "listPosition" : 39, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982296, "link" : "/api/reference/14982296", "label" : "40. Jenck, F., Broekkamp, C.L.E., Van Delft, A.M.L., The effect of anti-depressants on aversive periaqueductal gray stimulation in rats (1990) Eur J Pharmacol, 177, pp. 201-204", "listPosition" : 40, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982297, "link" : "/api/reference/14982297", "label" : "41. Olivier, B., Bosch, L., Van-Hest, A., Preclinical evidence on the psychotropic profile of fluvoxamine (1993) Pharmacopsychiatry, 26 (SUPPL. 1), pp. 2-9", "listPosition" : 41, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982298, "link" : "/api/reference/14982298", "label" : "42. Njung'e, K., Handley, S.L., Effects of 5-HT uptake inhibitors, agonists and antagonists on burying of harmless objects by mice; a putative test for anxiolytic agents (1991) Br J Pharmacol, 104, pp. 105-112", "listPosition" : 42, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982299, "link" : "/api/reference/14982299", "label" : "43. Woods, A., Smith, C., Szewczak, M., Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: A potential model for obsessive compulsive disorder (1993) Psychopharmacology, 112, pp. 195-198. , Sep", "listPosition" : 43, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982300, "link" : "/api/reference/14982300", "label" : "44. Leonard, B.E., Faherty, C., SSRIs and movement disorders: Is serotonin the culprit? (1996) Hum Psychopharm, 11, pp. S75-S82", "listPosition" : 44, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982301, "link" : "/api/reference/14982301", "label" : "45. Leonard, B.E., Movement disorders and abuse potential of the selective serotonin reuptake inhibitors (1999) Hum Psychopharm, 14, pp. 1-6", "listPosition" : 45, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982302, "link" : "/api/reference/14982302", "label" : "46. Van Harten, J., Overview of the pharmacokinetics of fluvoxamine (1995) Clin Pharmacokinet, 29 (SUPPL. 1), pp. 1-9", "listPosition" : 46, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982303, "link" : "/api/reference/14982303", "label" : "47. Perucca, E., Gatti, G., Spina, E., Clinical pharmacokinetics of fluvoxamine (1994) Clin Pharmacokinet, 27, pp. 175-190. , Sep", "listPosition" : 47, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982304, "link" : "/api/reference/14982304", "label" : "48. Catterson, M.L., Preskorn, S.H., Pharmacokinetics of selective serotonin reuptake inhibitors: Clinical relevance (1996) Pharmacol Toxicol, 78, pp. 203-208. , Apr", "listPosition" : 48, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982305, "link" : "/api/reference/14982305", "label" : "49. (1999) Luvox (fluvoxamine maleate) tablets, , Marietta, GA, USA, May", "listPosition" : 49, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982306, "link" : "/api/reference/14982306", "label" : "50. Hartter, S., Wetzel, H., Hammes, E., Nonlinear pharmacokinetics of fluvoxamine and gender differences (1998) Ther Drag Monit, 20, pp. 446-449. , Aug", "listPosition" : 50, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982307, "link" : "/api/reference/14982307", "label" : "51. Spigset, O., Granberg, K., Hagg, S., Non-linear fluvoxamine disposition (1998) Br J Clin Pharmacol, 45, pp. 257-263. , Mar", "listPosition" : 51, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982308, "link" : "/api/reference/14982308", "label" : "52. Hurst, M., Lamb, H.M., Fluoxetine: A review of its use in anxiety disorders and mixed anxiety and depression (2000) CNS Drags, 14 (1), pp. 51-80. , Jul", "listPosition" : 52, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982309, "link" : "/api/reference/14982309", "label" : "53. DeVane, C.L., Gill, H.S., Clinical pharmacokinetics of fluvoxamine: Applications to dosage regimen design (1997) J Clin Psychiatry, 58 (SUPPL. 5), pp. 7-14", "listPosition" : 53, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982310, "link" : "/api/reference/14982310", "label" : "54. Overmars, H., Scherpenisse, P.M., Post, L.C., Fluvoxamine maleate: Metabolism in man (1983) Eur J Drug Metab Pharmacokinet, 8 (3), pp. 269-280", "listPosition" : 54, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982311, "link" : "/api/reference/14982311", "label" : "55. Wright, S., Dawling, S., Ashford, J.J., Excretion of fluvoxamine in breast milk (1991) Br J Clin Pharmacol, 31, p. 209", "listPosition" : 55, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982312, "link" : "/api/reference/14982312", "label" : "56. De Vries, M.H., Raghoebar, M., Mathlener, I.S., Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects (1992) Ther Drug Monit, 14, pp. 493-498", "listPosition" : 56, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982313, "link" : "/api/reference/14982313", "label" : "57. Brennan, J., Hui, J., Pullen, R., Steady state pharmacokinetics of fluvoxamine in young and elderly volunteers (1998) Clin Pharmacol Ther, 63, p. 164. , Feb", "listPosition" : 57, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982314, "link" : "/api/reference/14982314", "label" : "58. Raghoebar, M., Roseboom, H., Kinetics of fluvoxamine in special populations (1988) Symposium on Variability in Pharmacokinetics and Drug Response, , Oct 3-5; Gothenburg, Sweden", "listPosition" : 58, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982315, "link" : "/api/reference/14982315", "label" : "59. Van Harten, J., Duchier, J., Devissaguet, J.-P., Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose administration (1993) Clin Pharmacokinet, 24 (2), pp. 177-182", "listPosition" : 59, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982316, "link" : "/api/reference/14982316", "label" : "60. Jeppesen, U., Gram, L.F., Vistisen, K., Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine (1996) Eur J Clin Pharmacol, 51, pp. 73-78. , Sep", "listPosition" : 60, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982317, "link" : "/api/reference/14982317", "label" : "61. Xu, Z.-H., Xie, H.-G., Zhou, H.-H., In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine (1996) Br J Clin Pharmacol, 42, pp. 518-521. , Oct", "listPosition" : 61, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982318, "link" : "/api/reference/14982318", "label" : "62. Jeppesen, U., Rasmussen, B.B., Brosen, K., Fluvoxamine inhibits the CYP2C 19-catalyzed bioactivation of chloroguanide (1997) Clin Pharmacol Ther, 62, pp. 279-286. , Sep", "listPosition" : 62, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982319, "link" : "/api/reference/14982319", "label" : "63. Von Moltke, L.L., Greenblatt, D.J., Court, M.H., Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants (1995) J Clin Psychopharmacol, 15, pp. 125-131. , Apr", "listPosition" : 63, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982320, "link" : "/api/reference/14982320", "label" : "64. Fleishaker, J.C., Hulst, L.K., A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine (1994) Eur J Clin Pharmacol, 46, pp. 35-39", "listPosition" : 64, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982321, "link" : "/api/reference/14982321", "label" : "65. Rasmussen, B.B., Maenpaa, J., Pelkonen, O., Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine (1995) Br J Clin Pharmacol, 39, pp. 151-159. , Feb", "listPosition" : 65, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982322, "link" : "/api/reference/14982322", "label" : "66. Brosen, K., Skjelbo, E., Rasmussen, B.B., Fluvoxamine is a potent inhibitor of cytochrome P4501A2 (1993) Biochem Pharmacol, 45, pp. 1211-1214", "listPosition" : 66, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982323, "link" : "/api/reference/14982323", "label" : "67. Pastrakuljic, A., Tang, B.K., Roberts, E.A., Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole (1997) Biochem Pharmacol, 21 Feb (53), pp. 531-538", "listPosition" : 67, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982324, "link" : "/api/reference/14982324", "label" : "68. Kashuba, A.D.M., Nafziger, A.N., Kearns, G.L., Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A (1998) Clin Pharmacol Ther, 63, p. 153. , Feb", "listPosition" : 68, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982325, "link" : "/api/reference/14982325", "label" : "69. Spigset, O., Are adverse drug reactions attributed to fluvoxamine caused by concomitant intake of caffeine (1998) Eur J Clin Pharmacol, 54, pp. 665-666. , Oct", "listPosition" : 69, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982326, "link" : "/api/reference/14982326", "label" : "70. Rasmussen, B.B., Nielsen, T.L., Brosen, K., Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro (1998) Pharmacol Toxicol, 83, pp. 240-245. , Dec", "listPosition" : 70, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982327, "link" : "/api/reference/14982327", "label" : "71. Jeppesen, U., Loft, S., Poulsen, H.E., A fluvoxamine-caffeine interaction study (1996) Pharmacogenetics, 6, pp. 213-222. , Jun", "listPosition" : 71, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982328, "link" : "/api/reference/14982328", "label" : "72. Armstrong, S.C., Stephans, J.R., Blood clozapine levels elevated by fluvoxamine: Potential for side effects and lower clozapine dosage (1997) J Clin Psychiatry, 58, p. 499. , Nov", "listPosition" : 72, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982329, "link" : "/api/reference/14982329", "label" : "73. Dequardo, J.R., Roberts, M., Elevated clozapine levels after fluvoxamine initiation (1996) Am J Psychiatry, 153, pp. 840-841. , Jun", "listPosition" : 73, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982330, "link" : "/api/reference/14982330", "label" : "74. Heeringa, M., Beurskens, R., Schouten, W., Elevated plasma levels of clozapine after concomitant use of fluvoxamine (1999) Pharm World Sci, 21 (5), pp. 243-244", "listPosition" : 74, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982331, "link" : "/api/reference/14982331", "label" : "75. Hiemke, C., Weigmann, H., Hartter, S., Elevated levels of clozapine in serum after addition of fluvoxamine (1994) J Clin Psychopharmacol, 14, pp. 279-281. , Aug", "listPosition" : 75, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982332, "link" : "/api/reference/14982332", "label" : "76. Olesen, O.V., Linnet, K., Fluvoxamine-clozapine drug interaction: Inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism (2000) J Clin Psychopharmacol, 20 (1), pp. 35-42. , Feb", "listPosition" : 76, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982333, "link" : "/api/reference/14982333", "label" : "77. Wetzel, H., Anghelescu, I., Szegedi, A., Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study (1998) J Clin Psychopharmacol, 18, pp. 2-9. , Feb", "listPosition" : 77, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982334, "link" : "/api/reference/14982334", "label" : "78. Markowitz, J.S., Gill, H.S., Lavia, M., Fluvoxamine-clozapine dose-dependent interaction (1996) Can J Psychiatry, 41, pp. 670-671. , Dec", "listPosition" : 78, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982335, "link" : "/api/reference/14982335", "label" : "79. DuMortier, G., Lochu, A., Colen-de-Melo, P., Elevated clozapine plasma concentrations after fluvoxamine initiation (1996) Am J Psychiatry, 153, pp. 738-739. , May", "listPosition" : 79, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982336, "link" : "/api/reference/14982336", "label" : "80. Koponen, H.J., Leinonen, E., Lepola, U., Fluvoxamine increases the clozapine serum levels significantly (1996) Eur Neuropsychopharmacol, 6, pp. 69-71. , Mar", "listPosition" : 80, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982337, "link" : "/api/reference/14982337", "label" : "81. Becquemont, L., Le Bot, M.A., Riche, C., Influence of fluvoxamine on tacrine metabolism in vitro: Potential implication for the hepatotoxicity in vivo (1996) Fundam Clin Pharmacol, 10, pp. 156-157", "listPosition" : 81, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982338, "link" : "/api/reference/14982338", "label" : "82. Becquemont, L., Ragueneau, I., Le Bot, M.A., Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans (1997) Clin Pharmacol Ther, 61, pp. 619-627. , Jun", "listPosition" : 82, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982339, "link" : "/api/reference/14982339", "label" : "83. Conus, P., Bondolfi, G., Eap, C.B., Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient (1996) Pharmacopsychiatry, 29, pp. 108-110. , May", "listPosition" : 83, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982340, "link" : "/api/reference/14982340", "label" : "84. Xu, Z.H., Huang, S.L., Zhou, H.H., Inhibition of imipramine N-demethylation by fluvoxamine in Chinese young men (1996) Chung Kuo Yao Li Hsueh Pao, 17, pp. 399-402. , Sep", "listPosition" : 84, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982341, "link" : "/api/reference/14982341", "label" : "85. Spina, E., Pollicino, A.M., Avenoso, A., Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients (1993) Int J Clin Pharmacol Res, 13 (3), pp. 167-171", "listPosition" : 85, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982342, "link" : "/api/reference/14982342", "label" : "86. Seifritz, E., Holsboer-Trachsler, E., Hemmeter, U., Increased trimipramine plasma levels during fluvoxamine comedication (1994) Eur Neuropsychopharmacol, 4, pp. 15-20. , Mar", "listPosition" : 86, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982343, "link" : "/api/reference/14982343", "label" : "87. Vandel, P., Bonin, B., Bertschy, G., Observations of the interaction between tricyclic antidepressants and fluvoxamine in poor metabolizers of dextromethorphan and mephenytoin (1997) Therapie, 52, pp. 74-76. , Jan-Feb", "listPosition" : 87, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982344, "link" : "/api/reference/14982344", "label" : "88. Van den Brekel, A.M., Harrington, L., Toxic effects of theophylline caused by fluvoxamine (1994) Can Med Assoc J, 1 Nov (151), pp. 1289-1290", "listPosition" : 88, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982345, "link" : "/api/reference/14982345", "label" : "89. Rasmussen, B.B., Jeppesen, U., Gaist, D., Griseofulvin and fluvoxamine interactions with the metabolism of theophylline (1997) Ther Drug Monit, 19, pp. 56-62. , Feb", "listPosition" : 89, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982346, "link" : "/api/reference/14982346", "label" : "90. DeVane, C.L., Markowitz, J.S., Hardesty, S.J., Fluvoxamine-induced theophylline toxicity (1997) Am J Psychiatry, 154, pp. 1317-1318. , Sep", "listPosition" : 90, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982347, "link" : "/api/reference/14982347", "label" : "91. Hemeryck, A., De Vriendt, C., Belpaire, F.M., Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)-warfarin using human liver microsomes (1999) Eur J Clin Pharmacol, 54, pp. 947-951. , Feb", "listPosition" : 91, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982348, "link" : "/api/reference/14982348", "label" : "92. Perucca, E., Gatti, G., Cipolla, G., Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers (1994) Clin Pharmacol Ther, 56, pp. 471-476. , Nov", "listPosition" : 92, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982349, "link" : "/api/reference/14982349", "label" : "93. Alderman, C.P., Frith, P.A., Fluvoxamine-methadone interaction (1999) Aust N Z J Psychiatry, 33, pp. 99-101. , Feb", "listPosition" : 93, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982350, "link" : "/api/reference/14982350", "label" : "94. Bertschy, G., Baumann, P., Eap, C.B., Probable metabolic interaction between methadone and fluvoxamine in addict patients (1994) Ther Drug Monit, 16, pp. 42-45. , Feb", "listPosition" : 94, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982351, "link" : "/api/reference/14982351", "label" : "95. Carrillo, J.A., Ramos, S.I., Herraiz, A.G., Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients (1999) J Clin Psychopharmacol, 19, pp. 494-499", "listPosition" : 95, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982352, "link" : "/api/reference/14982352", "label" : "96. Miljkovic, B.R., Pokrajac, M., Timotijevic, I., The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxaminelithium therapy (1997) Int Clin Psychopharmacol, 12, pp. 207-212. , Jul", "listPosition" : 96, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982353, "link" : "/api/reference/14982353", "label" : "97. Ochs, H.R., Greenblatt, D.J., Verburg-Ochs, B., Chronic treatment with fluvoxamine, clovoxamine, and placebo: Interaction with digoxin and effects on sleep and alertness (1989) J Clin Pharmacol, 29, pp. 91-95", "listPosition" : 97, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982354, "link" : "/api/reference/14982354", "label" : "98. Van Harten, J., Stevens, L.A., Raghoebar, M., Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function (1992) Clin Pharmacol Ther, 52, pp. 427-435", "listPosition" : 98, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982355, "link" : "/api/reference/14982355", "label" : "99. Diagnostic and statistical manual of mental disorders. Fourth ed., p. 1994. , Washington DC: American Psychiatric Association", "listPosition" : 99, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982356, "link" : "/api/reference/14982356", "label" : "100. Mundo, E., Bianchi, L., Bellodi, L., Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: A single-blind study (1997) J Clin Psychopharmacol, 17, pp. 267-271. , Aug", "listPosition" : 100, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982357, "link" : "/api/reference/14982357", "label" : "101. Goodman, W.K., Kozak, M.J., Liebowitz, M., Treatment of obsessive-compulsive disorder with fluvoxamine: A multicentre, double-blind, placebo-controlled trial (1996) Int Clin Psychopharmacol, 11, pp. 21-29. , Mar", "listPosition" : 101, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982358, "link" : "/api/reference/14982358", "label" : "102. Greist, J.H., Jenike, M.A., Robinson, D., Efficacy of fluvoxamine in obsessive-compulsive disorder: Results of a multicentre, double blind, placebo-controlled trial (1995) Eur J Clin Res, 7, pp. 195-204", "listPosition" : 102, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982359, "link" : "/api/reference/14982359", "label" : "103. Jenike, M.A., Hyman, S., Baer, L., A controlled trial of fluvoxamine in obsessive-compulsive disorder: Implications for a serotonergic theory (1990) Am J Psychiatry, 147, pp. 1209-1215. , Sep", "listPosition" : 103, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982360, "link" : "/api/reference/14982360", "label" : "104. Mallya, G.K., White, K., Waternaux, C., Short- and long-term treatment of obsessive-compulsive disorder with fluvoxamine (1992) Ann Clin Psychiatry, 4, pp. 77-80. , Jun", "listPosition" : 104, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982361, "link" : "/api/reference/14982361", "label" : "105. Mundo, E., Maina, G., Uslenghi, C., Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder (2000) Int Clin Psychopharmacol, 15, pp. 69-76. , Mar", "listPosition" : 105, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982362, "link" : "/api/reference/14982362", "label" : "106. Freeman, C.P.L., Trimble, M.R., Deakin, J.F.W., Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: A multicenter, randomized, double-blind, parallel group comparison (1994) J Clin Psychiatry, 55, pp. 301-305. , Jul", "listPosition" : 106, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982363, "link" : "/api/reference/14982363", "label" : "107. Rouillon, F., A double-blind comparison of fluvoxamine and clomipramine in OCD (1998) Eur Neuropsychopharmacol, 8 (SUPPL. 2), pp. S260-S261. , Nov", "listPosition" : 107, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982364, "link" : "/api/reference/14982364", "label" : "108. Koran, L.M., McElroy, S.L., Davidson, J.R.T., Fluvoxamine versus clomipramine for obsessive-compulsive disorder: A double-blind comparison (1996) J Clin Psychopharmacol, 16, pp. 121-129. , Apr", "listPosition" : 108, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982365, "link" : "/api/reference/14982365", "label" : "109. Milanfranchi, A., Ravagli, S., Lensi, P., A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder (1997) Int Clin Psychopharmacol, 12, pp. 131-136. , May", "listPosition" : 109, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982366, "link" : "/api/reference/14982366", "label" : "110. Goodman, W.K., Price, L.H., Rasmussen, S.A., Efficacy of fluvoxamine in obsessive-compulsive disorder: A double-blind comparison with placebo (1989) Arch Gen Psychiatry, 46, pp. 36-44. , Jan", "listPosition" : 110, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982367, "link" : "/api/reference/14982367", "label" : "111. Goodman, W.K., Price, L.H., Delgado, P.L., Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine (1990) Arch Gen Psychiatry, 47, pp. 577-585. , Jun", "listPosition" : 111, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982368, "link" : "/api/reference/14982368", "label" : "112. Nakajima, T., Kudo, Y., Yamashita, I., Clinical usefulness of fluvoxamine maleate (SME3110), a selective serotonin reuptake inhibitor, in the treatment of obsessive compulsive disorder: A double-blind, placebo-controlled study investigating the therapeutic dose range and the efficacy of SME3110 (1998) Rinsho Iyaku, 14 (3), pp. 589-616", "listPosition" : 112, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982369, "link" : "/api/reference/14982369", "label" : "113. Perse, T.L., Greist, J.H., Jefferson, J.W., Fluvoxamine treatment of obsessive-compulsive disorder (1987) Am J Psychiatry, 144 (12), pp. 1543-1548. , Dec", "listPosition" : 113, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982370, "link" : "/api/reference/14982370", "label" : "114. George, M.S., Trimble, M.R., Robertson, M.M., Fluvoxamine and sulpiride in comorbid obsessive-compulsive disorder and Gilles de la Tourette syndrome (1993) Hum Psychopharm, 8, pp. 327-334. , Sep-Oct", "listPosition" : 114, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982371, "link" : "/api/reference/14982371", "label" : "115. Ravizza, L., Barzega, G., Bellino, S., Drug treatment of obsessive-compulsive disorder (OCD): Long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs) (1996) Psychopharmacol Bull, 32 (1), pp. 167-173", "listPosition" : 115, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982372, "link" : "/api/reference/14982372", "label" : "116. Mundo, E., Bareggi, S.R., Pirola, R., Long-term pharmacotherapy of obsessive-compulsive disorder: A double-blind controlled study (1997) J Clin Psychopharmacol, 17, pp. 4-10. , Feb", "listPosition" : 116, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982373, "link" : "/api/reference/14982373", "label" : "117. Hohagen, F., Winkelmann, G., Rasche-Rauchle, H., Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo: Results of a multicentre study (1998) Br J Psychiatry, 173 (SUPPL. 35), pp. 71-78. , Aug", "listPosition" : 117, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982374, "link" : "/api/reference/14982374", "label" : "118. Cottraux, J., Mollard, E., Bouvard, M., Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: One-year follow-up (1993) Psychiatry Res, 49, pp. 63-75. , Oct", "listPosition" : 118, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982375, "link" : "/api/reference/14982375", "label" : "119. Hoehn-Saric, R., McLeod, D.R., Hipsley, P.A., Effect of fluvoxamine on panic disorder (1993) J Clin Psychopharmacol, 13 (5), pp. 321-326", "listPosition" : 119, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982376, "link" : "/api/reference/14982376", "label" : "120. Sandmann, J., Lorch, B., Bandelow, B., Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine (1998) Pharmacopsychiatry, 31, pp. 117-121. , Jul", "listPosition" : 120, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982377, "link" : "/api/reference/14982377", "label" : "121. Den Boer, J.A., Westenberg, H.G.M., Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline (1988) Int Clin Psychopharmacol, 3, pp. 59-74", "listPosition" : 121, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982378, "link" : "/api/reference/14982378", "label" : "122. Sharp, D.M., Power, K.G., Simpson, R.J., Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia (1996) J Anxiety Disord, 10, pp. 219-242. , Jul-Aug", "listPosition" : 122, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982379, "link" : "/api/reference/14982379", "label" : "123. Black, D.W., Wesner, R., Bowers, W., A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder (1993) Arch Gen Psychiatry, 50, pp. 44-50. , Jan", "listPosition" : 123, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982380, "link" : "/api/reference/14982380", "label" : "124. Van Vliet, I.M., Den Boer, J.A., Westenberg, H.G.M., A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder (1996) J Clin Psychopharmacol, 16 (4), pp. 299-306", "listPosition" : 124, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982381, "link" : "/api/reference/14982381", "label" : "125. Van Megen, H.J.G.M., Westenberg, H.G.M., Den Boer, J.A., Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks (1997) Psychopharmacology, 129, pp. 357-364. , Feb", "listPosition" : 125, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982382, "link" : "/api/reference/14982382", "label" : "126. Den Boer, J.A., Westenberg, H.G.M., Serotonin function in panic disorder: A double blind placebo controlled study with fluvoxamine and ritanserin (1990) Psychopharmacology, 102, pp. 85-94", "listPosition" : 126, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982383, "link" : "/api/reference/14982383", "label" : "127. Bakish, D., Hooper, C.L., Filteau, M.-J., A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia (1996) Psychopharmacol Bull, 32 (1), pp. 135-141", "listPosition" : 127, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982384, "link" : "/api/reference/14982384", "label" : "128. De Beurs, E., Van Balkom, A.J.L.M., Lange, A., Treatment of panic disorder with agoraphobia: Comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone (1995) Am J Psychiatry, 152 (5), pp. 683-691", "listPosition" : 128, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982385, "link" : "/api/reference/14982385", "label" : "129. De Beurs, E., Van Balkom, A.J.L.M., Van Dyck, R., Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: A 2-year naturalistic follow-up (1999) Acta Psychiatr Scand, 99, pp. 59-67", "listPosition" : 129, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982386, "link" : "/api/reference/14982386", "label" : "130. DeVane, C.L., Ware, M.R., Emmanuel, N.P., Evaluation of the efficacy, safety and physiological effects of fluvoxamine in social phobia (1999) Int Clin Psychopharmacol, 14, pp. 345-351. , Nov", "listPosition" : 130, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982387, "link" : "/api/reference/14982387", "label" : "131. Stein, M.B., Fyer, A.J., Davidson, J.R.T., Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study (1999) Am J Psychiatry, 156, pp. 756-760. , May", "listPosition" : 131, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982388, "link" : "/api/reference/14982388", "label" : "132. Van Vliet, I.M., Den Boer, J.A., Westenberg, H.G.M., Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine (1994) Psychopharmacology, 115, pp. 128-134", "listPosition" : 132, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982389, "link" : "/api/reference/14982389", "label" : "133. Marmar, C.R., Schoenfeld, F., Weiss, D.S., Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder (1996) J Clin Psychiatry, 57 (SUPPL. 8), pp. 66-72", "listPosition" : 133, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982390, "link" : "/api/reference/14982390", "label" : "134. De Boer, M., Op den Velde, W., Falger, P.J.R., Fluvoxamine treatment for chronic PTSD: A pilot study (1992) Psychother Psychosom, 57, pp. 158-163", "listPosition" : 134, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982391, "link" : "/api/reference/14982391", "label" : "135. Davidson, J.R.T., Weisler, R.H., Malik, M., Fluvoxamine in civilians with posttraumatic stress disorder (1998) J Clin Psychopharmacol, 18 (1), pp. 93-95. , Feb", "listPosition" : 135, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982392, "link" : "/api/reference/14982392", "label" : "136. Hollander, E., Obsessive-compulsive disorder-related disorders: The role of selective serotonergic reuptake inhibitors (1996) Int Clin Psychopharmacol, 11 (SUPPL. 5), pp. 75-87. , Dec", "listPosition" : 136, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982393, "link" : "/api/reference/14982393", "label" : "137. Hollander, E., Benzaquen, S.D., The obsessive-compulsive spectrum disorders (1997) Int Rev Psychiatry, 9, pp. 99-109", "listPosition" : 137, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982394, "link" : "/api/reference/14982394", "label" : "138. Fichter, M.M., Kruger, R., Rief, W., Fluvoxamine in prevention of relapse in bulimia nervosa: Effects on eating-specific psychopathology (1996) J Clin Psychopharmacol, 16, pp. 9-18. , Feb", "listPosition" : 138, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982395, "link" : "/api/reference/14982395", "label" : "139. Fichter, M.M., Leibl, C., Kruger, R., Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa (1997) Pharmacopsychiatry, 30, pp. 85-92. , May", "listPosition" : 139, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982396, "link" : "/api/reference/14982396", "label" : "140. Ayuso-Gutierrez, J.L., Palazon, M., Ayuso-Mateos, J.L., Open trial of fluvoxamine in the treatment of bulimia nervosa (1994) Int J Eat Disord, 15, pp. 245-249. , Apr", "listPosition" : 140, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982397, "link" : "/api/reference/14982397", "label" : "141. Hudson, J.I., McElroy, S.L., Raymond, N.C., Fluvoxamine in the treatment of binge-eating disorder: A multicenter placebo-controlled, double-blind trial (1998) Am J Psychiatry, 155, pp. 1756-1762. , Dec", "listPosition" : 141, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982398, "link" : "/api/reference/14982398", "label" : "142. Hollander, E., DeCaria, C.M., Mari, E., Short-term single-blind fluvoxamine treatment of pathological gambling (1998) Am J Psychiatry, 155, pp. 1781-1783. , Dec", "listPosition" : 142, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982399, "link" : "/api/reference/14982399", "label" : "143. Hollander, E., DeCaria, C.M., Finkell, J.N., A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling (2000) Biol Psychiatry, 47 (9), pp. 813-817", "listPosition" : 143, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982400, "link" : "/api/reference/14982400", "label" : "144. Hollander, E., Cohen, L., Simeon, D., Fluvoxamine treatment of body dysmorphic disorder (1994) J Clin Psychopharmacol, 14, pp. 75-77. , Feb", "listPosition" : 144, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982401, "link" : "/api/reference/14982401", "label" : "145. Phillips, K.A., Dwight, M.M., McElroy, S.L., Efficacy and safety of fluvoxamine in body dysmorphic disorder (1998) J Clin Psychiatry, 59, pp. 165-171. , Apr", "listPosition" : 145, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982402, "link" : "/api/reference/14982402", "label" : "146. Perugi, G., Giannotti, D., Di Vaio, S., Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia) (1996) Int Clin Psychopharmacol, 11, pp. 247-254. , Dec", "listPosition" : 146, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982403, "link" : "/api/reference/14982403", "label" : "147. Arnold, L.M., Mutasim, D.F., Dwight, M.M., An open clinical trial of fluvoxamine treatment of psychogenic excoriation (1999) J Clin Psychopharmacol, 19, pp. 15-18. , Feb", "listPosition" : 147, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982404, "link" : "/api/reference/14982404", "label" : "148. O'Sullivan, R.L., Phillips, K.A., Keuthen, N.J., Near-fatal skin picking from delusional body dysmorphic disorder responsive to fluvoxamine (1999) Psychosomatics, 40, pp. 79-81. , Jan-Feb", "listPosition" : 148, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982405, "link" : "/api/reference/14982405", "label" : "149. McDougle, C.J., Naylor, S.T., Cohen, D.J., A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder (1996) Arch Gen Psychiatry, 53, pp. 1001-1008. , Nov", "listPosition" : 149, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982406, "link" : "/api/reference/14982406", "label" : "150. Stanley, M.A., Breckenridge, J.K., Swann, A.C., Fluvoxamine treatment of trichotillomania (1997) J Clin Psychopharmacol, 17, pp. 278-283. , Aug", "listPosition" : 150, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982407, "link" : "/api/reference/14982407", "label" : "151. Black, D.W., Monahan, P., Gabel, J., Fluvoxamine in the treatment of compulsive buying (1997) J Clin Psychiatry, 58, pp. 159-163. , Apr", "listPosition" : 151, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982408, "link" : "/api/reference/14982408", "label" : "152. Chong, S.A., Low, B.L., Treatment of kleptomania with fluvoxamine (1996) Acta Psychiatr Scand, 93, pp. 314-315. , Apr", "listPosition" : 152, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982409, "link" : "/api/reference/14982409", "label" : "153. Durst, R., Katz, G., Knobler, H.Y., Buspirone augmentation of fluvoxamine in the treatment of kleptomania (1997) J Nerv Ment Dis, 185, pp. 586-588. , Sep", "listPosition" : 153, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982410, "link" : "/api/reference/14982410", "label" : "154. McElroy, S.L., Keck P.E., Jr., Pope H.G., Jr., Compulsive buying: A report of 20 cases (1994) J Clin Psychiatry, 55 (6), pp. 242-248", "listPosition" : 154, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982411, "link" : "/api/reference/14982411", "label" : "155. Black, D.W., Compulsive buying: A review (1996) J Clin Psychiatry, 57 (SUPPL. 8), pp. 50-55", "listPosition" : 155, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982412, "link" : "/api/reference/14982412", "label" : "156. Monahan, P., Black, D.W., Gabel, J., Reliability and validity of a scale to measure change in persons with compulsive buying (1996) Psychiatry Res, 30 Aug (64), pp. 59-67", "listPosition" : 156, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982413, "link" : "/api/reference/14982413", "label" : "157. Wagner, W., Zaborny, B.A., Gray, T.E., Fluvoxamine. A review of its safety profile in world-wide studies (1994) Int Clin Psychopharmacol, 9 (4), pp. 223-227", "listPosition" : 157, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982414, "link" : "/api/reference/14982414", "label" : "158. Edwards, J.G., Inman, W.H.W., Wilton, L., Prescription-event monitoring of 10401 patients treated with fluvoxamine (1994) Br J Psychiatry, 164, pp. 387-395. , Mar", "listPosition" : 158, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982415, "link" : "/api/reference/14982415", "label" : "159. Pollack, M.H., Psychopharmacology update (1997) J Clin Psychiatry, 58 (1), pp. 38-40. , Panic disorder: A treatment update. Jan", "listPosition" : 159, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982416, "link" : "/api/reference/14982416", "label" : "160. Ebert, D., Albert, R., May, A., The serotonin syndrome and psychosis-like side-effects of fluvoxamine in clinical use - An estimation of incidence (1997) Eur Neuropsychopharmacol, 7, pp. 71-74. , Feb", "listPosition" : 160, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982417, "link" : "/api/reference/14982417", "label" : "161. Lenzi, A., Raffaelli, S., Marazziti, D., Serotonin syndrome-like symptoms in a patient with obsessive-compulsive disorder, following inappropriate increase in fluvoxamine dosage (1993) Pharmacopsychiatry, 26, pp. 100-101. , May", "listPosition" : 161, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982418, "link" : "/api/reference/14982418", "label" : "162. Bastani, J.B., Troester, M.M., Bastani, A.J., Serotonin syndrome and fluvoxamine: A case study (1996) Nebr Med J, 81, pp. 107-109. , Apr", "listPosition" : 162, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982419, "link" : "/api/reference/14982419", "label" : "163. Hindmarch, I., The behavioural toxicity of antidepressants: Effects on cognition and sexual function (1998) Int Clin Psychopharmacol, 13 (SUPPL. 6), pp. S5-S8", "listPosition" : 163, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982420, "link" : "/api/reference/14982420", "label" : "164. Waldinger, M.D., Hengeveld, M.W., Zwinderman, A.H., Effect of SSRI antidepressants on ejaculation: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline (1998) J Clin Psychopharmacol, 18, pp. 274-281. , Aug", "listPosition" : 164, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982421, "link" : "/api/reference/14982421", "label" : "165. Montejo-Gonzalez, A.L., Llorca, G., Izquierdo, J.A., SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients (1997) J Sex Marital Ther, 23 (Fall), pp. 176-194", "listPosition" : 165, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982422, "link" : "/api/reference/14982422", "label" : "166. Haddad, P., The SSRI discontinuation syndrome (1998) J Psychopharmacol, 12, pp. 305-313. , Sep", "listPosition" : 166, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982423, "link" : "/api/reference/14982423", "label" : "167. Benazzi, F., SSRI discontinuation syndrome related to fluvoxamine (1998) J Psychiatry Neurosci, 23, p. 94. , Mar", "listPosition" : 167, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982424, "link" : "/api/reference/14982424", "label" : "168. Mallya, G., White, K., Gunderson, C., Is there a serotonergic withdrawal syndrome (1993) Biol Psychiatry, 33, pp. 851-852. , Jun 1-15", "listPosition" : 168, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982425, "link" : "/api/reference/14982425", "label" : "169. Coupland, N.J., Bell, C.J., Potokar, J.P., Serotonin reuptake inhibitor withdrawal (1996) J Clin Psychopharmacol, 16, pp. 356-362. , Oct", "listPosition" : 169, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982426, "link" : "/api/reference/14982426", "label" : "170. Price, J.S., Waller, P.C., Wood, S.M., A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal (1996) Br J Clin Pharmacol, 42, pp. 757-763. , Dec", "listPosition" : 170, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982427, "link" : "/api/reference/14982427", "label" : "171. Therrien, F., Markowitz, J.S., Selective serotonin reuptake inhibitors and withdrawal symptoms: A review of the literature (1997) Hum Psychopharm, 12, pp. 309-323. , Jul-Aug", "listPosition" : 171, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982428, "link" : "/api/reference/14982428", "label" : "172. (2000) CPMP position paper on selective serotonin uptake inhibitors (SSRIs) and dependency/withdrawal reactions, , http://www.eudra.org/humandocs/PDFs/PP/277599en.pdf, accessed Aug 23 [4 pages]", "listPosition" : 172, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982429, "link" : "/api/reference/14982429", "label" : "173. Barbey, J.T., Roose, S.P., SSRI safety in overdose (1998) J Clin Psychiatry, 59 (SUPPL. 15), pp. 42-48", "listPosition" : 173, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982430, "link" : "/api/reference/14982430", "label" : "174. Garnier, R., Azoyan, P., Chataigner, D., Acute fluvoxamine poisoning (1993) J Int Med Res, 21, pp. 197-208", "listPosition" : 174, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982431, "link" : "/api/reference/14982431", "label" : "175. Doogan, D.P., Toleration and safety of sertraline: Experience worldwide (1991) Int Clin Psychopharmacol, 6 (SUPPL. 2), pp. 47-56", "listPosition" : 175, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982432, "link" : "/api/reference/14982432", "label" : "176. Wernicke, J.F., The side effect profile and safety of fluoxetine (1985) J Clin Psychiatry, 46 (3 Sec. 2), pp. 59-67. , March", "listPosition" : 176, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982433, "link" : "/api/reference/14982433", "label" : "177. Mackay, F.J., Dunn, N.R., Wilton, L.V., A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies (1997) Pharmacoepidemiol Drug Saf, 6, pp. 235-246. , Jul-Aug", "listPosition" : 177, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982434, "link" : "/api/reference/14982434", "label" : "178. Ottevander, E.A., SSRI treatment-emergent nausea (1994) Neuropsychopharmacology, 10 (SUPPL. 3). , 104S", "listPosition" : 178, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982435, "link" : "/api/reference/14982435", "label" : "179. Meryn, S., De Zwaan, M., Schonbeck, G., Effect of overweight and weight reduction with dietary therapy and/or fluvoxamine on liver function in obesity (1990) Gastroenterology, 98 (5), pp. A607. , May", "listPosition" : 179, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982436, "link" : "/api/reference/14982436", "label" : "180. Harris, B., Ashford, J., Maintenance antidepressants and weight gain: A comparison of fluvoxamine and amitriptyline (1991) Br J Clin Res, 2, pp. 81-88", "listPosition" : 180, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982437, "link" : "/api/reference/14982437", "label" : "181. Harris, B., Szulecka, T.K., Anstee, J.A., Fluvoxamine versus amitriptyline in depressed hospital out-patients: A multicentre double-blind comparative trial (1991) Br J Clin Res, 2, pp. 89-99", "listPosition" : 181, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982438, "link" : "/api/reference/14982438", "label" : "182. Bennett, J.A., Moioffer, M., Stanton, S.P., A risk-benefit assessment of pharmacological treatments for panic disorder (1998) Drug Saf, 18 (6), pp. 419-430", "listPosition" : 182, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982439, "link" : "/api/reference/14982439", "label" : "183. Steffens, D.C., Krishnan, K.R.R., Helms, M.J., Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: A meta-analysis (1997) Depression Anxiety, 6, pp. 10-18", "listPosition" : 183, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982440, "link" : "/api/reference/14982440", "label" : "184. Roos, J.C., Cardiac effects of antidepressant drugs: A comparison of the tricyclic antidepressants and fluvoxamine (1983) Br J Clin Pharmacol, 15 (SUPPL. 3), pp. 439S-445S", "listPosition" : 184, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982441, "link" : "/api/reference/14982441", "label" : "185. Wagner, W., Houser, V., Wong, L.F., The safety profile of fluvoxamine in elderly patients (1996) Hum Psychopharm, 11, pp. 267-272. , Jul-Aug", "listPosition" : 185, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982442, "link" : "/api/reference/14982442", "label" : "186. Prager, G., Cimander, K., Wagner, W., The cardiotropic effect of antidepressants: A comparison with fluvoxamine (1986) Adv Pharmacother, 2, pp. 133-150", "listPosition" : 186, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982443, "link" : "/api/reference/14982443", "label" : "187. Strik, J.J., Honig, A., Lousberg, R., Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients (1998) Int Clin Psychopharmacol, 13 (6), pp. 263-267. , Nov", "listPosition" : 187, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982444, "link" : "/api/reference/14982444", "label" : "188. Harmant, J., Van Rijckevorsel-Harmant, K., De Barsy, T., Fluvoxamine: An antidepressant with low (or no) epileptogenic effect (1990) Lancet, 2, p. 386", "listPosition" : 188, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982445, "link" : "/api/reference/14982445", "label" : "189. Trabert, W., Hohagen, F., Winkelmann, G., A seizure, and electroencephalographic signs of a lowered seizure threshold, associated with fluvoxamine treatment of obsessive-compulsive disorder (1995) Pharmacopsychiatry, 28, pp. 95-97. , May", "listPosition" : 189, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982446, "link" : "/api/reference/14982446", "label" : "190. Regina, W., Vandel, S., Fluvoxamine and convulsive syncope: Case report (1998) Therapie, 53, pp. 504-505. , Sep-Oct", "listPosition" : 190, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982447, "link" : "/api/reference/14982447", "label" : "191. Fluvoxamine (2000) European summary of product characteristics, , http://www.solvay.com/depression/summeryofproduct.htm, [6 pages; revised 1998 Jul 7]. Accessed Jul 4", "listPosition" : 191, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982448, "link" : "/api/reference/14982448", "label" : "192. (2000) Limited-access program announced in United States to ensure appropriate use of Propulsid (cisapride): Product no longer to be promoted in United States, , www.us.janssen.com/news/current/propuls/imacc.html, [2 pages] Accessed May 30", "listPosition" : 192, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982449, "link" : "/api/reference/14982449", "label" : "193. Gottlieb, S., Antihistamine drug withdrawn by manufacturer (1999) BMJ, 319, p. 7", "listPosition" : 193, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982450, "link" : "/api/reference/14982450", "label" : "194. Friedman, M.A., Woodcock, J., Lumpkin, M.M., The safety of newly approved medicines: Do recent market removals mean there is a problem? (1999) JAMA, 281 (18), pp. 1728-1734", "listPosition" : 194, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982451, "link" : "/api/reference/14982451", "label" : "195. Anxiety disorders education campaign (2000), http://www.nmha.org/pbedu/anxiety/index.cfm, [1 page]. Accessed Jul 5Kobak, K.A., Greist, J.H., Jefferson, J.W., Behavioral versus pharmacological treatments of obsessive compulsive disorder: A meta-analysis (1998) Psychopharmacology, 136, pp. 205-216. , Apr", "listPosition" : 195, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982452, "link" : "/api/reference/14982452", "label" : "196. Ravizza, L., Maina, G., Bogetto, F., Long term treatment of obsessive-compulsive disorder (1998) CNS Drugs, 10 (4), pp. 247-255. , Oct", "listPosition" : 196, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982453, "link" : "/api/reference/14982453", "label" : "197. Cartwright, C., Hollander, E., SSRIs in the treatment of obsessive-compulsive disorder (1998) Depression Anxiety, 8 (SUPPL. 1), pp. 105-113", "listPosition" : 197, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982454, "link" : "/api/reference/14982454", "label" : "198. Panic disorder: A treatment update (1997) J Clin Psychiatry, 58 (1), pp. 36-42", "listPosition" : 198, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982455, "link" : "/api/reference/14982455", "label" : "199. Sheehan, D.V., Current concepts in the treatment of panic disorder (1999) J Clin Psychiatry, 60 (SUPPL. 18), pp. 16-21", "listPosition" : 199, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982456, "link" : "/api/reference/14982456", "label" : "200. Ninan, P.T., Issues in the assessment of treatment response in panic disorder with special reference to fluvoxamine (1997) J Clin Psychiatry, 58 (SUPPL. 5), pp. 24-31", "listPosition" : 200, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982457, "link" : "/api/reference/14982457", "label" : "201. Lecrubier, Y., Comorbidity in social anxiety disorder: Impact on disease burden and management (1998) J Clin Psychiatry, 59 (SUPPL. 17), pp. 33-37", "listPosition" : 201, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982458, "link" : "/api/reference/14982458", "label" : "202. Van Ameringen, M., Mancini, C., Oakman, J.M., Selective serotonin reuptake inhibitors in the treatment of social phobia: The emerging gold standard (1999) CNS Drugs, 11 (4), pp. 307-315. , Apr", "listPosition" : 202, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982459, "link" : "/api/reference/14982459", "label" : "203. Prakash, A., Foster, R.H., Paroxetine: A review of its use in social anxiety disorder (1999) CNS Drugs, 12, pp. 151-169. , Aug", "listPosition" : 203, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982460, "link" : "/api/reference/14982460", "label" : "204. Fichtner, C.G., Poddig, B.E., DeVito, R.A., Post-traumatic stress disorder: Pathophysiological aspects and pharmacological approaches to treatment (1997) CNS Drugs, 8 (4), pp. 293-322. , Oct", "listPosition" : 204, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982461, "link" : "/api/reference/14982461", "label" : "205. Baldwin, D., Rudge, S., The role of serotonin in depression and anxiety (1995) Int Clin Psychopharmacol, 9 (SUPPL. 4), pp. 41-45", "listPosition" : 205, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982462, "link" : "/api/reference/14982462", "label" : "206. Lane, R., Baldwin, D., Preskorn, S., The SSRIs: Advantages, disadvantages and differences (1995) J Psychopharmacol, 9 (2 SUPPL.), pp. 163-178", "listPosition" : 206, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982463, "link" : "/api/reference/14982463", "label" : "207. Stahl, S.M., Not so selective serotonin reuptake inhibitors (1998) J Clin Psychiatry, 59 (7), pp. 343-344. , Jul", "listPosition" : 207, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982464, "link" : "/api/reference/14982464", "label" : "208. Van Den Berg, S.J., Comparing SSRIs: From chemistry to clinical choice (1995) Hum Psychopharm, 10 (SUPPL. 3), pp. S199-S209. , Oct", "listPosition" : 208, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982465, "link" : "/api/reference/14982465", "label" : "209. Leonard, B.E., SSRI differentiation: Pharmacology and pharmacokinetics (1995) Hum Psychopharm, 10 (SUPPL. 3), pp. 149-158. , Oct", "listPosition" : 209, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 14982466, "link" : "/api/reference/14982466", "label" : "210. Hood, S.D., Argyropoulos, S.V., Nutt, D.J., Agents in development for anxiety disorders: Current status and future potential (2000) CNS Drugs, 13 (6), pp. 421-431. , Jun", "listPosition" : 210, "published" : false, "snippet" : true } ], "hasCitationDuplums" : false, "userChangeableUntil" : "2013-04-22T07:41:00.000+0000", "publishDate" : "2013-01-22T08:41:00.000+0000", "directInstitutesForSort" : "", "ownerAuthorCount" : 2, "ownerInstituteCount" : 11, "directInstituteCount" : 0, "authorCount" : 2, "contributorCount" : 0, "hasQualityFactor" : true, "link" : "/api/publication/22707462", "label" : "Figgitt DP et al. Fluvoxamine: An updated review of its use in the management of adults with anxiety disorders. (2000) DRUGS 0012-6667 1179-1950 60 4 925-954", "template" : "